Welcome back to our blog series on National Member News! We remain very excited about getting our National Member news out to the world, so more people can find out a lot more about what it is happening in each country and each organisation!

 

We caught up with Boryana Boteva from Lupus Bulgaria, who talked to us about the amazing work that Lupus Bulgaria are doing, the needs of lupus patients in Bulgaria, access to medications,  COVID19  and so much more!

 

            Photo of World Lupus Day Celebrations – 2017

 

How do you keep in touch with or have contact with your members?

 

That is a very good question! We have a very large facebook group, with about 6000 members. Members of our facebook group have all kinds of rheumatic and musculoskeletal diseases (RMDs); we have a number of members with lupus.

 

We talk to our members through our facebook group. We use the group to inform members about new administrative procedures or medication shortages.

 

Medication shortages can occur in Bulgaria, they are not an issue only because of the pandemic. During the pandemic we had a problem with hydroxychloroquine (HCQ). HCQ was not a registered medication for lupus, and this created serious access problems for people; thankfully it now is a registered medication. We have a Bulgarian brand of HCQ too, but unfortunately this is very expensive and the cost of HCQ cannot be reimbursed by the National Health Insurance Fund. People can buy HCQ through pharmacies, but they have to be able to cover the cost of the medication.


The only medication that is reimbursed completely by the National Health Insurance Fund in Bulgaria for lupus patients is Benlysta. People with other RMDs have coverage for other medications too through the National Health Insurance Fund, such as some biologics and corticosteroids. This is not the case for lupus patients.

 

The process to get a particular medication approved for coverage through the National Health Insurance Fund is complicated. For lupus patients, medications like Rituximab or Intravenous Immunoglobulins are not covered by the National Health Insurance Fund at all; they can only be used off label and patients have to cover the entire cost of the medications privately.

 

Our group has taken several actions to try to improve this situation for patients. We have campaigned, we have had conversations with the Minister of Health about the situation, but so far there has been no progress. One of the difficulties is that there is only an interim government in Bulgaria at the moment. National elections are due to take place in July; we hope to have a government after this time, and we hope the new government will try to make positive changes for people.

 

Did you have any special meetings or webinars during the past year (World Lupus Day, Rare Disease Day, Annual General Meeting etc)?

 

We have had a number of webinars for other RMDs this year, but we have not had webinars for lupus. Our facebook group is very active and we do regularly discuss problems lupus patients face in the facebook group.

 

We also created a survey this year. This was completed by patients with RMDs, including lupus. We wanted to find out how people feel, what they want to learn, what is their quality of life, what kind of access to treatment they have et cetera. We had 500 responses from people with rheumatic diseases; 170 of those 500 responses were from people with lupus.

 

We then presented the results of our survey to the media. We also wrote a letter to our Institutions, such as the National health insurance fund, the Ministry of Health etc, to inform them of the difficulties people face with access to treatment and of the fact that early diagnosis is still a problem for people.

 

We are hopeful things will improve with the new Health Minister. He is more open to talk with patient organisations, in fact he used to lead an organisation that deals with patients and doctors and problems in the healthcare system. He is a very different Health Minister because he has practical experience with how things actually are.

 

Has it been difficult to keep connected with your members during the Covid19 pandemic?

 

No, it was easy to keep connected with our members because of social media.

 

Have there been any circumstances during the pandemic that changed the way of living with lupus?

 

Contact with rheumatologists was very difficult before the pandemic, it became almost impossible during the pandemic. Unfortunately, like in most other countries, there was a lockdown. This meant that hospitals were closed, and this had an impact on the way people dealt with their chronic condition.

 

It wasn’t possible for people to have appointments with specialists during lockdown. People tried to talk with their doctors on the phone to have some healthcare during lockdown. Our  group became even more important; we tried to solve the problems people were facing together in the group during lockdown.

 

GPs were open during lockdown, but people could only talk with them on the phone; they couldn’t visit. Regular reviews and care were generally mostly over the phone for patients. Of course, if there was something urgent or life threatening, people could visit hospitals and be admitted.

 

The situation has thankfully gone back to normal now in terms of hospital appointments and reviews, because our covid19 numbers are lower.

 

Has Digital Health improved or changed in your country?

 

This is a very difficult issue. Digital Health in Bulgaria is very new, our Institutions are only just taking their first steps with digital health. For example, electronic prescriptions have just started to become established, but the reality of how they work is not how we imagined it would be.

 

So today I visited my GP to get my electronic prescription. This is very strange because even though the prescription is supposed to be electronic, I still have to physically go to the GP. I then had to wait and to take a code which I could then present to the pharmacist and then with that code I could pick up my medications. So, in terms of electronic prescriptions, patients have to physically go to the GP to sign a number of papers, the GP then receives a code that corresponds to the prescription, the GP records the medications being prescribed using that code, then writes the code in the patient’s medication prescription booklet and the patient then has to go to the pharmacy with the code to get the medication. This is not at all how we imagined electronic prescriptions would work.

 

There are some platforms for online consultations, but they’re not reimbursed by the National Health Insurance Fund. They are private platforms, where patients must cover the cost of the consultations, they are private consultations.  Some legal changes would have to be made to the system to allow patients to be reimbursed for online consultations. The government will work on this problem. In the future we hope things will be better in terms of online consultations for people.

 

Another difficulty in Bulgaria is that the medications that are covered by the National health insurance fund can only be prescribed by the GP. If a patient needs a medication that is not covered by the National Health Insurance Fund, then that can be prescribed by a specialist. For example, if a patient needs hydroxychloroquine (i.e. a medication that is not reimbursed), the rheumatologist can write that prescription. But if a patient needs Benlysta (i.e. a medication that is reimbursed), this should be prescribed by the GP. However, before the GP can prescribe the medication the patient would have to go before a Committee to get authorisation to use that medication. We have protocols last only for six months, so people have to go before the Committee every six months to get permission to continue their treatment. This is a very long process. The prices of medications are also higher compared to other European countries. This is not the case just with lupus medications, but for all RMDs.

 

During lockdown these protocols were prolonged by the government. Patients didn’t have to visit the Committee during lockdown, an exception was made. So, things were a little easier for lupus patients on Benlysta. But if a lupus patient needed to go on Benlysta for the first time then they either had to wait for lockdown to end or they had to take a risk (with covid19) and visit the Committee in person to submit their application. Most people waited for lockdown to end. 

 

The process to access Benlysta for a lupus patient is as follows. The doctor says a patient needs Benlysta and prepares a document to confirm this. The patient has tests, goes before the Committee for approval. Assuming the Committee approves the application, the patient has to retrieve the paperwork, go to the National Health Insurance Fund and deposit the paperwork there. The patient then has to wait two months to see if the National Health Insurance Fund approves the treatment or not.

 

It’s possible that the Committee may determine that a patient needs the treatment and approves it, but that then the National Health Insurance Fund rejects that person’s application. Even if the treatment is approved, the protocol only lasts for six months so patients have to repeat the entire process every six months. Thankfully when they submit an application to prolong (versus start) treatment the approval by the National Health Insurance Fund normally takes one month and not two. People have to time the approval process correctly so there are no gaps to their treatment. Some people do not go through this process because it’s very complicated and very long – too difficult for patients. In Bulgaria around 150 lupus patients use Benlysta.

 

GSK, the company that produces Benlysta, has now left Bulgaria. We are worried this will make the process to access Benlysta even more difficult for people in Bulgaria. GSK no longer has an office in Bulgaria. This is very sad. Our organisation has completed projects, funded by GSK, about lupus. In previous years we did a lot of things for lupus, we had a lot of meetings, we held roundtables on lupus; these projects were funded by GSK. It’s not clear we can keep such projects going without this funding. 

 

Lupus Awareness Week 2019 - Discussion on Problems Patients with Lupus Face in Bulgaria

Lupus Awareness Week 2019 – Discussion about Problems Lupus Patients Face 

 

  

What would you most need as support in your country for lupus?

 

We need information about the use of intravenous immunoglobulins (IVIG) in lupus patients. IVIG is used a lot in Bulgaria for lupus patients, we – as an organisation – want to explore whether there might be a possibility to have some trial data for this, so we might start the process to maybe get this registered and approved as a treatment for lupus patients here.

 

We also need information about new treatments and information about the situation in other countries compared to ours.

 

In terms of support for access to medications or to change legislation, it’s not sure anyone outside of Bulgaria can help us, we have to make changes by ourselves. The situation is incredibly individual to each country in terms of access to medications and legislation.  

 

Is there anything you think Lupus Europe could help your organisation with?  

 

We find the webinars and Conventions Lupus Europe organises very interesting. We share them in our facebook group, and we often translated them too. For example, the session by Petro Machado on Covid19 and people with RMDs, from the LUPUS EUROPE Convention in the Clouds – 2020, we shared it in our group, and we translated it into Bulgaria. This is a way you can help us: by continuing to organise such webinars, Conventions and meetings.

 

Is there any topic/theme/area that you think Lupus Europe should focus on, on something where European collaboration would make sense?

 

This is a difficult question. Our main problems relate to medication. We are not sure Lupus Europe can help us in this, but if you find a way when connecting with the European Medicines Agency (EMA) or in any other way we will be very happy to hear your suggestions.

 

There is also a big problem here with treatment approvals. Treatments are approved very late and the process for treatments to be approved is very hard. This significant delay in treatment approval is not unique to lupus, it happens in other conditions too; treatments are approved much later than in other countries. We hope that the EMA are aware of the delays with regards to treatment approvals and access to medications patients face in Bulgaria.

 

You sometimes collaborate with other countries – for example you bought some HCQ from Greece. Which countries do you collaborate with, for support or for medications?

 

People from Bulgaria travel to other countries like Greece, Germany, Turkey to buy HCQ. We don’t collaborate with organisations about this, people simply travel to those countries, buy HCQ and other medications for many people. This is a difficult process in some countries, because to get – for example HCQ in Greece– you need to have a local prescription from a local doctor.

 

We do have connections with other organisations through AGORA (i.e. a Platofrm of organisations of people with rheumatic diseases in Southern Europe) and through EULAR of course. The problems patients face in countries that are members of AGORA are similar, so it’s very useful to be a part of this platform.

 

We are trying very hard, and you know we are volunteers and things are becoming harder and harder.

 

Are you aware of the Lupus Europe Member Capacity Building Program?

 

Yes, we know about the capacity building program. We would like to know more about it.

 

Could you tell us a bit about a dream you have as a group?

 

We dream about access to medications that are accessible in other countries. We also dream about those medications being covered by the National Health Insurance Fund.

 

We dream about people being able to access psychological support, which is not at all covered in Bulgaria.  We were going to organise support groups for people with RMDs, including lupus, so people could access psychological support. The pandemic changed our plans, but now maybe we will try again to organise support groups.

 

We also dream of better connections with our doctors,  better communication.

 

It will be interesting to read about what other LUPUS EUROPE National Member organisations dream about; are they having the same problems that we are having?

 

There are a lot of things we dream for, but these are the most important and the most basic let’s say.  [/vc_column_text][/vc_column][/vc_row]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

💜 We've taken part in the EULAR PARE Conference 2026 in Brussels! And what an interesting opportunity to discuss the future of AI in healthcare!

🌍 Bringing together more than 100 delegates and speakers from across Europe and beyond, the conference explored some of the most important questions surrounding artificial intelligence in rheumatology and patient advocacy.

From the opportunities and risks of AI to health inequalities, accessibility and European health policy, the discussions highlighted why patient perspectives must be part of the conversation.

🤩 We were particularly proud to see Jeanette Andersen, Chair of the Lupus Europe Board, sharing our experience with #LupusGPT in her presentation, “AI as a Partner in Care: Empowering the RMD Community with Information”.

💡 Jeanette explained how #LupusGPT was developed with patients and clinicians to offer free, multilingual access to reliable lupus information based on validated sources.

She also introduced #EasyLupus, which provides the same trusted information in simpler language, highlighting why accessibility must be considered when developing AI tools.

But one of the most important messages from her presentation went beyond technology.

💜 Patient organisations have much more to contribute to AI than simply using tools developed by others.

As Jeanette highlighted, patient organisations bring lived experience, knowledge of unmet needs, trusted information and an understanding of the barriers people face when accessing health information.

Technology alone cannot tell us what patients really need or what makes a tool genuinely useful.

Patients and patient organisations should not simply be users of AI. They should help shape its development.

👏 A big thank you to EULAR PARE for bringing together so many different perspectives and creating space for meaningful discussions about the future of healthcare and patient involvement!
...

💜 Weve taken part

🦋 One of the greatest strengths of patient organisations is the support, understanding and sense of community they offer to people living with lupus. 💜

🇧🇬 A great example comes from Организация на пациентите с ревматологични заболявания, who shared their psychological support initiative at the #LupusConvention!

💜 Launched in December 2025, this pilot project provides a safe and supportive space where participants can share their experiences and discuss the challenges of living with lupus, from fatigue and anxiety to relationships and everyday life.

👥 Led by a clinical psychologist, the group currently brings together six women. The project is expected to run until December 2026, while the organisation explores funding opportunities to continue and expand the initiative.

Thank you to our Bulgarian colleagues for sharing their experience, and congratulations on the amazing job you are doing! ❤️

🌍 This is just one example of the valuable work patient organisations are doing across Europe, often responding to needs that go beyond medical care. We'll share more in the coming days!

💜 Are you living with lupus? You don't have to navigate everything alone! Your national lupus organisation may offer information, support, activities and opportunities to connect with others who understand your experiences.

🔗 Find your national lupus organisation and get in touch:
lupus-europe.org/lupus-members/
...

Image attachment
Image attachment

💜 Young people living with lupus are not only the future of patient advocacy. Their voices matter today!

On 23 and 24 October, LUPUS EUROPE was delighted to be represented at the first 𝗘𝗣𝗙 𝗬𝗼𝘂𝘁𝗵 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Brussels by Ana Rita Vieira, from the LUPUS EUROPE Youth Group, and Lena Koskina, LUPUS EUROPE's Youth Group Coordinator.

🌍 Organised by European Patients' Forum and its EPF Youth Group, the Congress brought together young patient advocates from across Europe to explore the challenges facing young people living with chronic conditions, from economic uncertainty and climate change to the barriers they encounter when trying to influence healthcare decisions.

🌟 One particularly important question ran through the discussions: 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝘆 𝗴𝗶𝘃𝗶𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗵𝗮𝘃𝗲 𝗮 𝗿𝗲𝗮𝗹 𝘀𝗮𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝗶𝗻𝗴 𝗺𝗮𝗱𝗲❓

The conversations also highlighted something easily overlooked: 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻. Young people living with chronic conditions are often balancing their health with education, employment and financial pressures. Advocacy opportunities need to recognise those realities, and not be accessible only to those who can afford the time and resources to participate.

🦋 At LUPUS EUROPE, supporting the Youth Group means actively helping create those opportunities, connecting young advocates with others across Europe and ensuring their perspectives can meaningfully contribute to the work we do.

Young people living with lupus are already advocates, bringing their experiences, ideas and knowledge into conversations that matter.

💜 Thank you to European Patients' Forum and its EPF Youth Group for bringing everyone together, and to Rita and Lena for representing LUPUS EUROPE at this important Congress!
...

💜 Young people li

🔊 Hot off the press!

💜 Treatment adherence is important, complex and multifactorial.

But understanding the importance of treatment adherence is not the same as knowing how to support it in everyday clinical practice.

That’s why, in 2020, EULAR published its Points to Consider for the prevention, screening, assessment and management of nonadherence to treatment in people with rheumatic and musculoskeletal diseases.

But having recommendations is only the first step. How can we ensure they become part of everyday clinical practice?

🤩 An interesting new viewpoint published in EULAR Rheumatology Open, co-authored by Jeanette Andersen, Chair of the Lupus Europe Board, now explores the challenges of putting these recommendations into routine rheumatology care.

The article highlights that nonadherence is not simply a matter of individual patient behaviour. Concerns about treatment, practical difficulties, access to medication, socioeconomic circumstances and communication with healthcare professionals can all play a role.

The authors highlight five key priorities for putting adherence support into routine rheumatology practice:

🔹 Assessment: Identifying adherence behaviours and the barriers behind them.
🔹 Monitoring: Reassessing adherence over time, as it may change throughout the disease course.
🔹 Shared decision-making: Discussing patients’ preferences, expectations and concerns through non-judgemental communication.
🔹 Multidisciplinary care: Involving the wider healthcare team according to individual needs.
🔹 Training: Making adherence support part of rheumatology education and professional development.

💜 The challenge is not the lack of recommendations, but making adherence assessment and support a routine part of rheumatology care.

📖 Read the open-access viewpoint: doi.org/10.1016/j.ero.2026.100261
...

Image attachment
Image attachment
Image attachment
Image attachment
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send